EDMONTON, ALBERTA -- (MARKET WIRE) -- November 09, 2006 -- ViRexx Medical Corp. (TSX: VIR)(AMEX: REX), a company focused on immunotherapy treatments for certain cancers, chronic hepatitis B & C and embolotherapy treatments for solid tumors, today announced its financial and operational results for the third quarter and nine-month period ended September 30, 2006.
